Nuformix (LSE:NFX) reported interim results showing continued progress for NXP002, its lead inhaled treatment candidate targeting idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. The company recently secured U.S. FDA Orphan Drug Designation for the enabled form of tranilast used within the programme, adding to the European Medicines Agency orphan designation already granted for the therapy.
Management said the dual orphan status is helping to strengthen ongoing discussions with potential partners regarding licensing or broader collaboration opportunities. Preclinical studies have also continued to demonstrate strong anti-fibrotic and anti-inflammatory activity from NXP002, both as a standalone treatment and when used alongside existing standard-of-care therapies.
Improved Financial Position Supports Development Strategy
Nuformix reported a reduced half-year loss of £346,577, while loss per share improved to 0.02p. The company’s financial position was supported by a heavily oversubscribed open offer followed by a separate £1 million share subscription.
As a result, cash and cash equivalents increased to £930,283, while net assets rose to £1.64 million. The company said the newly raised funds are being directed toward generating additional value-enhancing data for NXP002 and refining the programme in line with feedback from prospective commercial partners.
Management believes this strategy could improve the prospects of securing an out-licensing agreement and help advance the programme toward clinical development in what is expected to become a rapidly expanding IPF treatment market.
Financial Constraints Continue to Weigh on Outlook
The company’s outlook is primarily constrained by weak financial performance (no recent revenue, ongoing losses, and persistent cash burn), partially offset by a low-debt balance sheet. Technicals are modestly negative with the price below key moving averages, and valuation provides limited support due to a negative P/E and no dividend yield data.
More about Nuformix Plc
Nuformix plc is a UK-based pharmaceutical development company focused on targeting unmet medical needs in fibrosis and oncology through drug repurposing. It leverages expertise in discovering and patenting novel forms of existing drugs with improved physical properties, aiming to create differentiated products in terms of dose, delivery route or presentation and to secure early-stage licensing opportunities from its preclinical pipeline. Nuformix shares trade on the Main Market of the London Stock Exchange under the ticker NFX, giving the company access to public capital to fund development of assets such as its lead inhaled therapy NXP002 for fibrotic lung diseases.
Leave a Reply